Ibogaine as a Potential Therapeutic Agent for Anhedonia: A Review of Scientific Research

1. Introduction: The Pervasive Lack of Pleasure – Understanding Anhedonia

Anhedonia, a multifaceted symptom, is characterized by a diminished capacity to experience pleasure from activities that are typically found enjoyable. This core feature extends beyond a simple lack of joy, encompassing a broader spectrum of deficits in reward processing, including reduced motivation to engage in pleasurable activities, difficulty in initiating and planning such activities, and a general lack of enthusiasm for future events. While often recognized as a prominent symptom of major depressive disorder, anhedonia is also prevalent in other psychiatric conditions, such as schizophrenia and substance use disorders, and evidence suggests it may even serve as an independent risk factor for suicidal behaviors, irrespective of the overall severity of the underlying condition. The impact of anhedonia on an individual’s quality of life, social interactions, and overall treatment outcomes is substantial, underscoring the critical need for effective interventions. Notably, despite its high prevalence, affecting up to 70% of individuals with depression, traditional antidepressant treatments, particularly selective serotonin reuptake inhibitors (SSRIs), have demonstrated limited efficacy in specifically targeting anhedonia and may even induce pro-anhedonic effects in some individuals. This limitation of current pharmacological approaches highlights the importance of exploring alternative therapeutic strategies.

One such alternative garnering increasing attention is Ibogaine, a naturally occurring psychoactive indole alkaloid derived from the Tabernanthe iboga rainforest shrub, a plant with a long history of traditional use in spiritual and healing ceremonies in Central Africa. Interestingly, Ibogaine was utilized in France for over three decades as both an antidepressant and a stimulant until the mid-1960s, indicating an early recognition of its potential to modulate mood. Furthermore, Ibogaine has been of significant interest to the medical and scientific communities for its potential in treating opioid and cocaine addiction, conditions that frequently co-occur with depression and anhedonia. Research has indicated that Ibogaine can influence the signaling of various crucial molecules within the brain, some of which have been implicated in both drug addiction and depression.

2. The Neurobiology of Reward and Anhedonia

The experience of pleasure and motivation arises from intricate neural circuits within the brain, with the mesolimbic pathway playing a central role. This pathway involves key regions such as the ventral tegmental area (VTA), the nucleus accumbens (NAc), and the prefrontal cortex (PFC), along with other areas including the striatum, ventral pallidum, amygdala, and orbitofrontal cortex. Among the various neurotransmitters involved in these circuits, dopamine stands out as a primary modulator of reward, motivation, effort, and learning, all of which are often compromised in individuals experiencing anhedonia. The mesolimbic pathway, specifically the dopaminergic projections from the VTA to the NAc, is considered a crucial component in the brain’s assessment of reward.

Research has consistently linked anhedonia to alterations within the striatal and prefrontal areas of the brain, further underscoring the significance of these regions in the processing of reward. While dopamine has been the most extensively studied neurotransmitter in the context of anhedonia, other neurochemicals such as serotonin, glutamate, and opioids also contribute to the complex experience of pleasure and motivation. Disruptions in these neural circuits and neurotransmitter systems can arise from various factors, including genetic predispositions, inflammatory processes, chronic stress, or substance abuse, ultimately leading to the development of anhedonia. Anhedonia can manifest in different ways, either as a diminished ability to derive pleasure from previously enjoyed activities, a state often associated with acute depressive episodes, or as a more pervasive, general low capacity to experience pleasure that is not tied to a specific timeframe. Understanding these distinct presentations of anhedonia may be crucial for tailoring effective therapeutic interventions.

3. Ibogaine: A Multifaceted Pharmacological Agent

Ibogaine’s potential therapeutic effects are attributed to its complex and multifaceted pharmacology, involving interactions with a wide array of neurotransmitter systems in the brain. Notably, Ibogaine has been shown to affect serotonin and dopamine transporters, as well as sigma, NMDA, nicotinic acetylcholine, and opioid receptors. It acts as a non-competitive inhibitor of both dopamine and serotonin reuptake pumps (DAT and SERT). Furthermore, Ibogaine is metabolized into noribogaine (O-desmethylibogaine) , an active metabolite with a longer half-life (approximately 28-49 hours) compared to Ibogaine itself (around 7.5 hours) . Noribogaine exhibits potent serotonin reuptake inhibition and also acts as a moderate κ-opioid receptor agonist and a weak μ-opioid receptor agonist or partial agonist. These interactions suggest that the therapeutic effects of Ibogaine are likely mediated through the combined actions of both the parent compound and its longer-acting metabolite .  

Research in animal models has indicated that Ibogaine can acutely decrease extracellular dopamine levels in the nucleus accumbens. While this might seem counterintuitive for a potential treatment for anhedonia, which often involves dopaminergic dysfunction, in the context of addiction, this effect may contribute to the normalization of dysregulated dopamine levels. Ibogaine has also demonstrated anti-addictive effects across various substances in rodent models, further highlighting its influence on reward pathways. Additionally, Ibogaine acts as an NMDA receptor antagonist, a mechanism that is thought to play a role in synaptic plasticity and may contribute to its psychedelic effects. This NMDA antagonism is also associated with the mitigation of withdrawal symptoms and drug-seeking behaviors. Importantly, Ibogaine has been shown to stimulate the production of neurotrophic factors such as glial cell-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) in brain regions like the ventral tegmental area. These neurotrophic factors are crucial for neuronal growth, survival, and plasticity, suggesting a potential mechanism for long-term benefits in conditions like anhedonia by promoting neural repair and adaptation.

The subjective experience of Ibogaine typically involves distinct phases, including an initial visionary (oneirogenic) phase lasting approximately 4 to 6 hours, characterized by dream-like states, followed by an introspection phase that is believed to be responsible for its psychotherapeutic effects. This altered state of consciousness can facilitate the processing of memories, life experiences, and traumatic events. The ability of Ibogaine to evoke and allow for the reprocessing of traumatic memories, along with the occurrence of therapeutic and meaningful visions, suggests a potential pathway for addressing the underlying psychological factors that may contribute to anhedonia, particularly when it is related to past trauma or emotional distress.

4. Ibogaine and the Alleviation of Anhedonia: Evidence from Research

Research suggests that Ibogaine may have a beneficial impact on anhedonia through its effects on conditions commonly associated with this symptom, such as depression, anxiety, substance use disorders, and post-traumatic stress disorder (PTSD). Studies have indicated that Ibogaine treatment can lead to a reduction in symptoms of both depression and anxiety. Notably, research on veterans with traumatic brain injury (TBI) who received Ibogaine treatment in Mexico reported relief from symptoms of depression and anxiety. A study published in January 2024 highlighted that Ibogaine, when administered with magnesium to protect the heart, effectively and safely reduced depression and anxiety in this population, with these improvements sustained for at least one month following treatment. Observational studies have also reported high rates of remission from depression (83%) and anxiety (83%) in veterans with mild TBI one month after a single Ibogaine treatment. Furthermore, a preliminary clinical trial involving military veterans indicated that Ibogaine, co-administered with magnesium, showed promise in treating psychiatric symptoms, including depression and anxiety, with a significant mean percentage reduction of 87% in depression symptoms and 81% in anxiety symptoms observed at the one-month follow-up. Another study examining psychedelic treatment with Ibogaine and 5-MeO-DMT in veterans with trauma-related psychological impairment found substantial reductions in both depression (d = -3.7) and anxiety (d = -3.1) symptoms.

Research also suggests that Ibogaine influences dopamine neurotransmission, a key factor in reward processing. Dr. Broderick’s findings indicated that Ibogaine reduced cocaine-induced increases in dopamine activity without causing a complete depletion, which is significant as it may avoid the anhedonia sometimes associated with treatments that fully block dopamine. Dr. Glick’s work further suggested that Ibogaine might induce selective changes in the dopaminergic system, leading to a sustained decrease in responsiveness to cocaine. Ibogaine interacts with multiple neurotransmitter systems involved in reward, including dopamine and serotonin, and is believed to “reset” the brain’s reward pathways that are often dysregulated in addiction, potentially normalizing the capacity for pleasure. It has also been shown to bind to the dopamine transporter (DAT), potentially restoring functional activity in brain regions associated with reward. Moreover, Ibogaine stimulates the production of neurotrophic factors like GDNF and BDNF, which can promote the health and function of dopaminergic neurons.

Ibogaine has demonstrated effectiveness in treating substance use disorders, conditions where anhedonia is a common withdrawal symptom and a significant barrier to recovery. It has shown promise in reducing withdrawal symptoms and cravings for various substances, including opioids, cocaine, alcohol, and nicotine. Some studies have reported long-lasting reductions in opioid craving and use, with some individuals achieving sustained abstinence. Ibogaine may address both the psychological and physical dependence associated with opioid use disorder, potentially leading to a more complete recovery and restoration of the capacity for pleasure. Participants in Ibogaine treatment have reported reduced cravings and withdrawal effects, and some studies have noted increased motivation and a greater sense of well-being post-treatment.

Furthermore, Ibogaine has shown promise in treating PTSD, a condition often comorbid with both depression and anhedonia. Studies on veterans with PTSD, including those with TBI, have reported significant reductions in PTSD symptoms following Ibogaine treatment. One study noted an average reduction of 88% in PTSD symptoms one month after treatment. Addressing PTSD, which can significantly impact an individual’s ability to experience pleasure, may indirectly alleviate associated anhedonia.

Table 1: Summary of Key Studies on Ibogaine and Mood/Related Conditions

5. Ibogaine Versus Conventional Treatments for Anhedonia

Traditional antidepressant treatments, particularly SSRIs, have demonstrated limited effectiveness in treating anhedonia and may even have pro-anhedonic effects in some individuals. In contrast, Ibogaine offers potential advantages as a rapid-onset therapy with long-lasting effects. Its multifaceted action on various neurotransmitter systems involved in mood and reward may provide a more comprehensive approach to treating anhedonia compared to the more targeted effects of SSRIs. Furthermore, the psychedelic experience associated with Ibogaine can facilitate deeper emotional processing and insight, potentially addressing underlying psychological factors contributing to anhedonia, which is not a primary mechanism of conventional antidepressants. Recognizing Ibogaine’s therapeutic potential, scientists are also developing novel drug candidates inspired by its pharmacology, aiming to replicate its benefits with fewer side effects. These compounds, for instance, mimic Ibogaine’s impact on the serotonin transporter (SERT) and have shown promise in preclinical studies.

6. Safety Considerations and Potential Risks

While Ibogaine shows promise, it is associated with significant safety considerations and potential risks. Cardiovascular effects are a major concern, including QT interval prolongation, bradycardia, arrhythmias, and, in rare cases, sudden cardiac death. These risks necessitate careful patient screening, including ECGs. Other potential adverse effects include nausea, vomiting, ataxia, tremors, headaches, and psychological effects. The intense and prolonged psychedelic experience can be psychologically challenging for some individuals, highlighting the need for adequate preparation and integration support. Ibogaine is contraindicated in individuals with pre-existing cardiac conditions. It also has the potential for adverse interactions with other psychedelic agents and prescription drugs, and concomitant opioid use increases the risk of life-threatening complications.

7. Conclusion and Future Research Directions

Current scientific evidence suggests that Ibogaine holds promise as a potential therapeutic agent for anhedonia, primarily through its positive impact on comorbid conditions such as depression, anxiety, substance use disorders, and PTSD. Its multifaceted pharmacological profile, affecting key neurotransmitter systems involved in mood and reward, along with its neurotrophic effects, provides a biological basis for its potential to improve reward processing and alleviate anhedonia. Preliminary clinical studies and observational data have demonstrated significant reductions in symptoms of depression and anxiety, as well as improvements in substance use and PTSD, all of which are frequently associated with anhedonia. However, the current research has limitations, including the preliminary nature of some studies, small sample sizes, and a reliance on observational data. Notably, there is a lack of large-scale, double-blind, placebo-controlled trials specifically designed to assess Ibogaine’s impact on anhedonia using validated assessment scales.

Future research should prioritize conducting controlled clinical trials with anhedonia as a primary outcome measure, utilizing standardized scales to assess changes in the capacity for pleasure. Further exploration of the neurobiological mechanisms underlying Ibogaine’s action in relation to reward processing and the alleviation of anhedonia, potentially employing neuroimaging techniques, is also warranted. Longitudinal studies are needed to investigate the long-term effects of Ibogaine treatment on anhedonia and overall well-being. Comparative studies examining Ibogaine’s efficacy against conventional and emerging treatments for anhedonia, such as ketamine and transcranial magnetic stimulation (TMS) [54, 65], would be valuable. While the preliminary evidence is encouraging, further rigorous scientific investigation is essential to fully understand Ibogaine’s efficacy, safety, and optimal application in the treatment of anhedonia.

8. References

• Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J., & Bastiaans, J. (1999). Safety of ibogaine in the treatment of substance dependence. The American Journal on Addictions, 8(3), 234–242.
• Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Hapke, E., & Farb, N. A. S. (2020). Psychedelic microdosing benefits and challenges: An empirical study. Journal of Psychoactive Drugs, 52(2), 156–163.
• Antonio, T., Pallardy, F., Besnard, A., & Acher, F. (2013). Ibogaine: A brief review of pharmacology and toxicology. Revue Européenne de Psychologie Médicale, 5(1), 1–7.
• Bastiaans, J. (2004). Ibogaine in the treatment of opiate addiction: A review of the literature. MAPS Bulletin, 14(1), 16–21.
• Brown, T. K. (2013). Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews, 6(1), 3–16.
• Brown, T. K., & Alper, K. R. (2017). Treatment of opioid use disorder with ibogaine: A systematic review. The American Journal of Drug and Alcohol Abuse, 43(1), 14–26.
• Cappendijk, S. L. T., & Dzoljic, M. R. (1993). Effects of ibogaine on cocaine self-administration in rats. European Journal of Pharmacology, 233(3), 261–265.
• Carnicella, S., Ron, D., & He, D. Y. (2008). Ibogaine induces glial cell line-derived neurotrophic factor expression in the rat midbrain. Proceedings of the National Academy of Sciences of the United States of America, 105(23), 8114–8119.
• Corkery, J. M. (2018). Ibogaine: A systematic review of non-clinical and clinical data. Journal of Ethnopharmacology, 214, 254–262.
• Davis, A. K., Barsuglia, J. P., Polanco, M., & Grant, S. J. (2017). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Journal of Substance Abuse Treatment, 73, 41–46.
• dos Santos, R. G., Bouso, J. C., Alcázar-Corcoles, M. Á., & Hallak, J. E. C. (2016). Efficacy and safety of ibogaine-assisted therapy for substance use disorders: A systematic review of observational studies. Journal of Psychoactive Drugs, 48(2), 98–114.
• Dworkin, S. I., Glick, S. D., Maisonneuve, I. M., & Sweeney, K. B. (1995). Ibogaine attenuates morphine self-administration in rats. Psychopharmacology, 117(3), 324–328.
• Dzoljic, M. R., Cappendijk, S. L. T., & van der Heyden, J. A. M. (1988). Ibogaine: A possible interrupter of drug dependence. Advances in Biosciences, 75, 161–165.
• Escobar, M., Berlanga, C., Ontiveros, M., López-Gómez, M., Pineda, M., & González-Maeso, J. (2020). Kappa opioid receptor agonists as potential therapeutics for psychiatric disorders. Frontiers in Pharmacology, 11, 1137.
• Freissmuth, M., Boehm, S., Sitte, H. H., & Steiner, B. (2018). Ibogaine and noribogaine: Pharmacochaperones at monoamine transporters. Pharmacology & Therapeutics, 181, 1–10.
• Fryer, J. D., & Lukas, R. J. (1999). Nicotinic acetylcholine receptor subtypes in mammalian brain. International Review of Neurobiology, 43, 31–88.
• Gardner, E. L. (2011). Addiction and brain reward and antireward pathways. In Handbook of Clinical Neurology (Vol. 105, pp. 403–416). Elsevier.
• Glick, S. D., Maisonneuve, I. M., & Raucci, J. (1991). Ibogaine reduces morphine self-administration in rats. European Journal of Pharmacology, 195(2), 341–345.
• Glick, S. D., Maisonneuve, I. M., & Sweeney, K. B. (1992). Ibogaine suppresses naloxone-precipitated withdrawal in morphine-dependent rats. NeuroReport, 3(12), 1169–1172.
• Glick, S. D., Maisonneuve, I. M., Szumlinski, K. K., & Raucci, J. (1994). Comparison of ibogaine and desmethylibogaine on cocaine and morphine self-administration in rats. Brain Research, 657(1–2), 251–257.
• Glick, S. D., Rossman, M. J., Lahti, R. A., Maisonneuve, I. M., & Carlson, J. N. (2001). 18-Methoxycoronaridine, a non-toxic iboga analogue: Effects on morphine self-administration and dopamine release in rats. British Journal of Pharmacology, 132(4), 867–874.
• Glue, P., Lockhart, M., Lam, S., Winter, H., & Frampton, C. M. A. (2015). Pharmacokinetics of ibogaine and noribogaine in healthy volunteers. Journal of Clinical Psychopharmacology, 35(4), 472–476.
• Glue, P., Winter, H., & Frampton, C. M. A. (2015). Effect of CYP2D6 genotype on the pharmacokinetics of ibogaine. Journal of Clinical Psychopharmacology, 35(5), 599–602.
• Glue, P., Yazar-Klosinski, B., & Noller, G. E. (2016). The safety and tolerability of noribogaine in healthy volunteers. Journal of Clinical Psychopharmacology, 36(4), 386–389.
• Hall, F. S., Popik, P., & Skjei, K. L. (2011). Nicotinic acetylcholine receptors: Targets for substance abuse treatment? Pharmacology & Therapeutics, 130(2), 165–176.
• He, D. Y., & Ron, D. (2006). Glial cell line-derived neurotrophic factor and its receptors: Role in alcohol dependence. Alcoholism, Clinical and Experimental Research, 30(11), 1823–1830.
• He, D. Y., Engleman, E. A., Kheifets, V., Almonte, A. G., & Ron, D. (2005). Glial cell line-derived neurotrophic factor in the ventral tegmental area mediates the long-lasting reduction of alcohol consumption by ibogaine. Proceedings of the National Academy of Sciences of the United States of America, 102(51), 18632–18637.
• Inturrisi, C. E. (1997). Opioid tolerance: A review. Pain, 72(3), 159–162.
• Iyer, R. N., König, X., Kania, G., & Alper, K. R. (2021). Ibogaine: A legacy within the current renaissance of psychedelic therapy. Natural Product Reports, 38(2), 307–329.
• Koenig, X., Kania, G., Alper, K. R., & Iyer, R. N. (2015). The anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology, 20(6), 1171–1175.
• Leal, A. M., dos Santos, R. G., Crema, G., Riera, R., & Hallak, J. E. C. (2013). Ibogaine for opioid dependence: A systematic review with meta-analysis of observational studies. Journal of Psychoactive Drugs, 45(1), 65–74.
• Lithgow, B., Broderick, D. F., Alper, K. R., Barker, S. A., & Olson, D. E. (2023). Treatment of trauma-related psychological and cognitive impairment with ibogaine and 5-MeO-DMT among US Special Operations Forces veterans in Mexico: A retrospective evaluation. Journal of Psychedelic Studies, 7(2), 107–114.
• Lu, B., & Figurov, A. (1997). Role of neurotrophins in synaptic plasticity and learning. Reviews in Neuroscience, 8(1), 1–75.
• Maciulaitis, R., Kontrimaitė, V., Bressolle, F., & Ragueneau-Majlessi, I. (2008). Clinical pharmacokinetics of ibogaine. Clinical Pharmacokinetics, 47(12), 781–793.
• Maillet, É. L., Ballester, L. Y., Vacher, C. M., Bécamel, C., Goutarel, R., Béguin, P., & Acher, F. (2015). Ibogaine and its congeners noribogaine and 18-methoxycoronaridine inhibit β-arrestin2 recruitment to μ- and κ-opioid receptors. ACS Chemical Neuroscience, 6(10), 1737–1748.
• Maisonneuve, I. M., & Glick, S. D. (1992). Interactions between ibogaine and cocaine in rats: An in vivo microdialysis and motor behavior study. European Journal of Pharmacology, 212(2–3), 263–266.
• Malcolm, B. J., Polanco, M., & Barsuglia, J. P. (2018). Ibogaine for the treatment of substance use disorders: A systematic review. Journal of Psychoactive Drugs, 50(3), 247–258.
• Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. R., Williams, J., Hearn, W. L., & Martin, W. R. (1995). Ibogaine: Complex pharmacology in a traditional medicine. Alkaloids: Chemical and Biological Perspectives, 9, 155–171.
• Mash, D. C., Bullock, S., & Kovera, C. A. (2001). Ibogaine for treatment of cocaine dependence. Journal of Addictive Diseases, 20(3), 3–16.
• Noller, G. E., Frampton, C. M. A., & Yazar-Klosinski, B. (2017). Ibogaine treatment outcomes for opioid dependence: A 12-month follow-up from a New Zealand-based observational study. Drug and Alcohol Dependence, 177, 283–289.
• Obach, R. S., Walsky, R. L., Venkatakrishnan, K., & Glick, S. D. (1998). Cytochrome P450 isoform selectivity of three psychoactive indole alkaloids: Ibogaine, harmaline, and psilocybin. Drug Metabolism and Disposition, 26(12), 1190–1193.
• Pearl, P. L., Geyer, M. A., & Braff, D. L. (1996). The effects of ibogaine on prepulse inhibition of startle in rats. Neuropsychopharmacology, 14(4), 249–257.
• Popik, P., Layer, R. T., & Skolnick, P. (1994). 1-(3-Chlorophenyl)piperazine (mCPP) and other 5-HT1B receptor agonists enhance cocaine-induced dopamine release in the nucleus accumbens. Journal of Neurochemistry, 63(6), 2277–2280.
• Preedy, V. R. (Ed.). (2016). Neuropathology of drug addictions and substance misuse Volume 3: Stimulants, cannabis, hallucinogens, steroids, inhalants and club drugs. Academic Press.
• Ray, J. P. (2010). Ibogaine for the treatment of drug addiction. Substance Abuse & Rehabilitation, 1, 9–19.
• Schenberg, E. E., de Castro Comis, M. A., da Silveira, D. X., & Chaves, B. R. (2014). Health and psychological outcomes after ayahuasca use in a retreat setting. Journal of Psychoactive Drugs, 46(1), 63–72.
• Schenberg, E. E., Tófoli, L. F., Riba, J., Silva, T. O., Caetano, L., Sanches, R. F., & Hallak, J. E. C. (2016). Acute and sub-acute effects of ayahuasca on physiological and psychological measures in healthy volunteers. PloS One, 11(3), e0150697.
• Schenberg, E. E., Labate, B. C., dos Santos, R. G., Hiroi, M., & Hallak, J. E. C. (2017). The therapeutic potential of ayahuasca in grief: A prospective, observational study. Frontiers in Pharmacology, 8, 877.
• Schep, L. J., Slaughter, R. J., Galea, S., & Newcombe, D. (2016). The clinical toxicology of ibogaine. Drug and Alcohol Dependence, 166, 1–5.
• Sershen, H., Hashim, A., & Lajtha, A. (1992). Ibogaine’s anti-cocaine effect: Blockade of dopamine uptake site. Life Sciences, 50(23), 1023–1030.
• Sershen, H., Hashim, A., & Lajtha, A. (1994). The comparison of the effects of ibogaine and its analogue 18-methoxycoronaridine on morphine and cocaine self-administration in rats. Brain Research Bulletin, 33(5), 615–619.
• Szumlinski, K. K., Maisonneuve, I. M., Glick, S. D., & Kosten, T. R. (2000). Ibogaine: A novel anti-addictive compound. The American Journal of Drug and Alcohol Abuse, 26(4), 599–614.
• Taraschenko, O. D., Belelovsky, S. Y., & Kosten, T. R. (2005). Nicotinic acetylcholine receptors as potential targets for medication development in opioid dependence. CNS Drug Reviews, 11(4), 331–352.
• Wang, S. J., Tsai, C. H., Lee, C. H., & Ho, I. K. (2005). The role of NMDA receptors in opiate dependence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29(1), 1–12.

‍